A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

Doctors have raised serious concerns about the efficacy of AstraZeneca's Brilinta, which is given to people with a history of heart attack or blood vessel conditions that put them at risk of ...

Soriot said that IoT technology is already helping patients get access to drugs such as its platelet therapy, Brilinta. Soriot said: “We can leverage digital tools to better treat patients.